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Abstract: The epithelium-specific ETS (ESE) transcription factors (ELF3, ELF5, EHF and SPDEF) are
defined by their highly conserved ETS DNA binding domain and predominant epithelial-specific
expression profile. ESE transcription factors maintain normal cell homeostasis and differentiation
of a number of epithelial tissues, and their genetic alteration and deregulated expression has been
linked to the progression of several epithelial cancers. Herein we review the normal function of the
ESE transcription factors, the mechanisms by which they are dysregulated in cancers, and the current
evidence for their role in cancer progression. Finally, we discuss potential therapeutic strategies for
targeting or reactivating these factors as a novel means of cancer treatment.
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1. Introduction
The epithelium-specific ETS (ESE) transcription factors are a sub-group of the larger E26
transformation-specific (ETS) transcription factor family, of which there are 28 members in humans
and 27 in mice [1]. All ETS factors share a conserved 85 amino acid (aa) ETS DNA binding domain [2],
and regulate gene expression by binding to the core GGAA/T regulatory sequence where the H3 helix
of the ETS domain inserts into the major groove of DNA [2].
The ESE transcription factors can be divided into two groups based on the homology of the ETS
DNA binding domain–(1) ELF3, ELF5 and EHF and (2) SPDEF–but are grouped together based on their
common epithelial-specific expression profile. In addition to the ETS domain, all ESE members share
an N-terminal Pointed (PNT) domain comprising ~80 aa’s [3], which is similar to the evolutionarily
conserved sterile alpha motif (SAM) domain (Figure 1). SAM/(PNT) domains perform a range of
functions, including mediating protein-protein interactions, kinase docking, RNA-binding and lipid
molecule interactions, as well as transcriptional activation [4].
ESE transcription factors play a key role in normal development, as well as differentiation and
homeostasis of specific epithelial tissues. We will review these processes by describing the expression
profile of ESE factors in normal tissues, focussing on the phenotypes of ESE factor knockout mice
which have been described in detail for Elf3, Elf5 and Spdef. ESE factors have also been implicated
in the pathogenesis of a wide range of cancers, with both oncogenic and tumour suppressive roles
described depending on the specific ESE factor and tumour type. We also review the current knowledge
regarding the role of each ESE factor in cancer progression, focussing on their genetic alteration, altered
expression, association with outcome, and mechanisms of action.
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Figure 1. Schematic representation of the epithelial-epecific ETS transcription factors. Adapted from
Feldman et al., 2003 [5] and Archer et al., 2017 [6].
1.1. Role of ELF3 in Normal Tissue Homeostasis
ELF3 is located on chromosome 1q32.1 and encodes a 371 aa protein. Analysis of the mRNA
expression profile of ELF3 across normal human tissues reveals highest expression in the gastrointestinal
tract (esophagus, large and small intestine and stomach), with strong expression also in the salivary
gland, bladder, liver and prostate (Figure 2). As the role of ELF3 in normal epithelial tissues has been
previously reviewed [7], we only briefly summarize these findings below.
Figure 2. Expression of ELF3 mRNA across normal human tissues. Data obtained from University of
California Santa Cruz (UCSC) genome browser.
1.1.1. Elf3 Knockout Mice
Whole body knockout of Elf3 results in embryonic lethality in ~30% of mice at ~E11.5 [8]. Of the
Elf3−/− mice which are born, over half die prior to weaning due to development of diarrhea and a
wasted phenotype suggestive of malnourishment, although interestingly, those animals which survive
the first 6 weeks gain weight normally [8].
1.1.2. ELF3 in the Intestinal Epithelium
A likely cause of the wasted phenotype of Elf3−/− mice is the abnormal differentiation of the
small intestinal epithelium, where the enterocytes contain fewer microvilli and display loss of polarity,
and the number of differentiated goblet cells is reduced. TgfβRII mRNA expression is reduced in
the intestinal epithelium of Elf3−/− mice, and crossing Elf3−/− mice with intestinal-specific TgfβRII
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transgenic mice rescues the Elf3−/− phenotype, demonstrating that ELF3 maintains intestinal cell
differentiation through activating TGFβ-signalling [9].
1.1.3. ELF3 in the Lung Epithelium
Elf3−/− mice also show delayed bronchial epithelial regeneration following naphthalene-induced
Clara cell injury, indicating a role for Elf3 in regulating proliferation and differentiation in this
context [10]. As observed in the intestine, expression of TgfβRII, which is a key factor required for
epithelial differentiation is reduced in the bronchial epithelium of Elf3−/− mice, which may contribute
to the phenotype [10].
1.1.4. ELF3 in the Urothelium
ELF3 protein is expressed in differentiated superficial urothelial cells and ELF3 mRNA
and protein expression is increased during PPARγ-induced differentiation of normal human
urothelial cells in vitro [11]. ELF3 knockdown in this model attenuates expression of key urothelial
differentiation-inducing transcription factors (FOXA1 and GRHL3), and markers of urothelial
differentiation, establishing a direct requirement for ELF3 for urothelial differentiation [11].
1.1.5. ELF3 in Squamous Epithelium
ELF3 mRNA is induced during terminal differentiation of the epidermis [12], and directly drives
expression of the terminal differentiation marker SPRR2A through binding to consensus ETS binding
sites within its promoter [12]. ELF3 also induces expression of SPRR2A in oesophageal and cervical
squamous epithelial cell lines [13], while in parallel repressing expression of the early marker of
differentiation, KRT4, indicative of a dual function in promoting squamous epithelial differentiation.
Elf3 mRNA is also expressed in the differentiated mouse corneal epithelium and is induced
during human corneal epithelial differentiation in vitro. ELF3 overexpression transactivates the KRT12
promoter, and ELF3 knockdown reduces morphological features of squamous epithelial differentiation,
establishing a direct role in the differentiation process [14].
1.1.6. ELF3 in Non-Epithelial Cells
While ELF3 is primarily expressed in epithelial cells, it also plays a role in vascular inflammation
and remodeling [15]. ELF3 mRNA and protein is induced in primary endothelial cells and vascular
smooth muscle cells upon stimulation with proinflammatory cytokines or angiotensin II, and Elf3−/−
mice stimulated with angiotensin II display increased T cell and macrophage infiltration into the vessel
wall, increased vascular thickening and fibrosis, and have an exaggerated systolic blood pressure
response. Induction of the Elf3 target gene, nitric oxide synthase 2 (Nos2), is also attenuated in
vascular smooth muscle cells in Elf3−/− mice, raising the possibility that Elf3 may normally act to
balance inflammatory responses in this tissue by inducing nitric oxide production by driving Nos2
expression [15].
Recently, a role for ELF3 in contributing to cartilage degradation was demonstrated in a model
of post-traumatic osteoarthritis. ELF3 protein is overexpressed in the cartilage of patients with
osteoarthritis, and drives expression of the IL-1β-induced genes MMP13, NOS2, and PTGS2/COX2
in chondrocytes [16]. Conditional deletion of Elf3 in mouse chondrocytes results in decreased
IL-1β-mediated induction of Mmp13 and Nos2, and these mice undergo less cartilage loss in a model
of osteoarthritis. Conversely, chondrocyte-specific Elf3 overexpression induces the opposite effect [17].
Finally, Elf3 is suggested to regulate allergic airway inflammation, as Elf3−/− mice display
an impaired Th17 response to pulmonary inflammatory challenge. Specifically, Elf3−/− dendritic
cells produce lower levels of IL-12, a key cytokine required for Th1 differentiation, resulting in an
exaggerated Th2 inflammatory response [18].
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1.2. Role of ELF3 in Cancer
Mutations in ELF3, particularly inactivating mutations, occur in bladder, cervical, ovarian and
a number of gastrointestinal cancers, including cancers of the biliary tract, stomach and colon.
Conversely, gene amplification of ELF3 occurs in some of these same cancers (colorectal, gastric),
as well as in breast and liver cancer (Figure 3).
Figure 3. Frequency of genomic alterations in ELF3 in human cancers. Data obtained from cancer
bioportal [19,20]. Only showing cancers in which >50 cases were analysed.
1.2.1. ELF3 in Bladder Cancer
A recent exome-sequencing study of bladder cancer performed by The Cancer Genome Atlas
(TCGA) consortium reported mutations in ELF3 in ~6% of both superficial and invasive tumours,
over half of which were inactivating mutations [21]. Comparatively, categorization of bladder cancers
into luminal or basal subtypes identified more frequent ELF3 mutations in luminal tumours [22,23].
While the inactivating mutations in ELF3 would suggest a tumour suppressive role, the functional
significance of these mutations in disease pathogenesis has yet to be directly established in cell line or
animal models.
1.2.2. ELF3 in Ovarian Cancer (OC)
Similar to bladder cancer, inactivating and splice site mutations in ELF3 occur in ~6% of mucinous
OCs [24]. Furthermore, loss of ELF3 mRNA and protein expression is associated with poorer outcome
in OC, collectively suggesting a tumour suppressive role [25]. Consistent with such a role, re-expression
of ELF3 in OC cell lines with low endogenous expression inhibits proliferation in vitro and in vivo,
and promotes mesenchymal to epithelial transition (MET). Conversely, ELF3 knockdown in OC cell
lines induced epithelial to mesenchymal transition (EMT), suggesting ELF3 inhibits ovarian tumour
progression by maintaining the epithelial state [25].
1.2.3. ELF3 in Biliary Tract Cancers
Inactivating mutations in ELF3 occur in ~6% of cholangiocarcinomas [26,27] and gallbladder
cancers [28,29], and in ~10% of ampullary cancers [30,31], which arise from the Ampulla of Vater,
the nipple-like projection into the duodenum into which the pancreatic and bile ducts open. Ampullary
cancers originate from the different epithelial cell types present at the site, and ELF3 mutations
occur in both intestinal-type and pancreatobiliary-type ampullary adenocarcinomas. Furthermore,
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ELF3 mutations in ampullary tumours occur in high allele frequencies suggesting they are likely
founder mutations. The majority of ELF3 truncating mutations in biliary tract cancer are heterozygous,
suggesting ELF3 may act as a haplo-insufficient tumour suppressor [30]. Consistent with such a role,
knockdown of ELF3 in an immortalized epithelial cell line of common bile duct origin increased cell
invasion and motility, and promoted EMT [30], while re-expression of ELF3 in a cholangiocarcinoma
cell line harbouring a heterozygous frameshift mutation inhibited proliferation [26].
1.2.4. ELF3 in Gastric and Colorectal Cancer
ELF3 is mutated in 2–4% of gastric cancers (GCs) and colorectal cancers (CRCs), and deleted in
a further ~1% of GCs (Figure 3). As for bladder and biliary tract cancers, the majority of mutations
are truncating, suggestive of a tumour suppressive role. Notably, the TCGA also identified ELF3
amplifications in ~1–2% of GCs and CRCs, while a study by Wang et al. suggested this rate may be as
high as 17% [32]. Wang et al. also reported increased ELF3 protein expression in CRC compared to the
adjacent normal epithelium, and an association of high ELF3 protein and mRNA expression with worse
overall survival. Overexpression of ELF3 in CRC cells increased cell proliferation and transcription of
β-catenin, suggesting a novel means of driving WNT signaling in these tumours [32]. On the other
hand, Yang et al. demonstrated that ELF3 co-localizes and physically interact with β-catenin in CRC
cells [33]. Intriguingly, this complex forms in the cytoplasm, raising the possibility that ELF3 may act
to sequester β-catenin away from the nucleus and dampen β-catenin-driven transcription.
Additional studies, including experiments in animal models, are still required to resolve these
discrepancies and definitively establish the role of ELF3 in gastric and CRC progression.
1.2.5. ELF3 in Cervical Cancer
Frameshift mutations in ELF3 occur in ~13% of cervical adenocarcinomas [34], which surprisingly
express higher levels of ELF3 mRNA compared to wild-type tumours. This may be due to futile
overexpression of the mutant allele, or compensatory upregulation of the wild-type allele. Whether
these mutations are homo or heterozygous, and the effect of these mutations on tumour initiation and
progression, remains to be determined [34].
1.2.6. ELF3 in Breast Cancer
Studies in breast cancer suggest ELF3 may function as either a tumour promoter or suppressor,
depending on the molecular subtype of the disease. In Estrogen Receptor α (ERα) positive breast
cancer, ELF3 directly binds and represses the transcriptional activity of ERα, suggestive of a tumour
suppressive role. Ectopic expression of ELF3 also reduced ERα target gene expression, and decreased
oestrogen-dependent proliferation of MCF7 cells, whereas ELF3 knockdown in the same cell line
induced the opposite effects [35]. ELF3 was also itself found to be an ERα target gene, suggesting it
may act as a negative feedback regulator of ERα signaling [35]. Similarly, in triple negative breast
cancer (TNBC), ELF3 mRNA expression is lower in primary tumours compared to normal breast
epithelium, and further reduced in distant metastases [36]. Interestingly, sorting of TNBC organoids
into more differentiated or stem-like populations revealed higher ELF3 mRNA expression in the
differentiated population. ELF3 mRNA was also induced following pharmacological induction of
TNBC cell differentiation, and knockdown and overexpression experiments demonstrated ELF3 was
required for the differentiation-inducing effect of this drug treatment [36].
Conversely, ELF3 may have a pro-tumorigenic role in HER2+ tumours, where ELF3 is upregulated
due to HER2-signaling driven activation of the ELF3 promoter [37,38]. HER2+ breast cancers with
high ELF3 mRNA expression have a worse outcome, and ELF3 knockdown in HER2+ breast cancer
cell lines attenuated tumour growth through inhibition of AKT signaling [39]. ELF3 knockdown also
inhibited the growth in HER2+ trastuzumab-resistant breast cancer cell lines [40].
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1.2.7. ELF3 in Prostate Cancer
ELF3 mRNA and protein expression are increased in primary prostate cancers compared to
normal prostate tissue, and further increased in metastases [41]. ELF3 is also amplified in 2–6% of
tumours collectively suggesting a role in tumour progression. The high ELF3 expression in prostate
cancers is driven, at least in part, by the pro-inflammatory cytokine IL-1β, in a NF-κB-dependent
manner. In turn, ELF3 interacts with NF-κB and enhances NF-κB-driven transcription, creating a
positive feedback loop which constitutively activates NF-κB and promotes prostate cancer progression.
Notably, the subset of prostate cancers which express high levels of both ELF3 and nuclear NF-κB (p65)
have a significantly worse prognosis [41]. Further to this, stable expression of ELF3 in LNCaP and
22RV1 prostate cancer cells increased proliferation, colony formation, cell migration and resistance to
anoikis in vitro, and promoted formation of lung metastases in vivo [41].
In contrast, Shatnawi et al. reported a putative tumour suppressive function for ELF3 in prostate
cancer [42]. While they did identify a subset of prostate cancers with increased ELF3 mRNA expression,
they observed downregulation of ELF3 mRNA in the majority of primary tumours. Furthermore,
a direct interaction between ELF3 and the androgen receptor (AR) was identified in LNCaP cells,
which was enhanced upon treatment with an androgen agonist. Further studies established ELF3 as a
repressor of AR activity contributing to the repression of AR target genes. ELF3 overexpression also
attenuated the proliferation of AR agonist stimulated LNCaP cells in vitro, and repressed the growth
of LNCaP xenografts in vivo [42]. Collectively, these findings suggest that loss of ELF3 represents
an additional means of enhancing AR activity in prostate cancer cells. The basis for the disparity of
these findings with those of Longoni et al. [41] is unclear, as the same cell line (LNCaP) was used in
both studies, although notably, several of the effects reported by Shatnawi et al. were in the context of
androgen agonist treatment.
1.2.8. ELF3 in Lung Cancer
ELF3 mRNA and protein expression is elevated in non-small cell lung cancer (NSCLC) compared
to corresponding normal lung tissue, with high expression associated with poor patient outcome.
Furthermore, functional studies demonstrated that ELF3 knockdown inhibited proliferation, metastasis
and EMT of lung cancer cell lines, and inhibited PI3K/AKT and ERK signalling [43], suggesting a
tumour promoting role in these cancers.
1.2.9. ELF3 in Hepatocellular Cancer (HCC)
High protein expression of ELF3 in HCC is also associated with a poor patient outcome,
and knockdown of ELF3 in HCC cell lines decreased proliferation, migration and invasion. ELF3
overexpression also promoted EMT as evidenced by the increased expression of mesenchymal
markers N-Cadherin and fibronectin, and the EMT driver ZEB1. These effects were driven through
ELF3-mediated suppression of miR-141-3p, which in turn resulted in overexpression of ZEB1 [44].
1.3. Role of ELF5 in Normal Tissue Homeostasis
ELF5 is located on chromosome 11p13 and encodes a 265 aa protein. Analysis of normal human
tissues indicates ELF5 mRNA expression is restricted to only a few epithelial tissues with highest
expression in the salivary gland, breast and bladder, and some expression in the lung, kidney and skin
(Figure 4).
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Figure 4. Expression of ELF5 mRNA across normal human tissues. Data obtained from UCSC
genome browser.
1.3.1. Elf5 Knockout Mice
Two groups have generated Elf5 knockout mice and both demonstrated that constitutive Elf5
deletion results in embryonic lethality [45,46]. Elf5−/− embryos implant at expected Mendelian ratios
but no Elf5−/− embryos survive beyond E7.5. Subsequent studies demonstrated that Elf5-deficient
embryos fail to develop the extraembryonic ectoderm due to terminal differentiation of trophoblast
stem cells [46,47], resulting in severe patterning defects and failure of the embryos to undergo
gastrulation [46].
1.3.2. ELF5 in the Mammary Epithelium
Elf5 is required for the proliferation and differentiation of mammary alveolar epithelial cells
during pregnancy and lactation, as loss of even one allele of Elf5 (Elf5+/− mice) results in complete
developmental arrest of the mammary gland [45]. These findings were confirmed in mammary-specific
Elf5−/− mice where mammary epithelial cells had disorganized cell structures and reduced milk
production [48]. Subsequent studies demonstrated that Elf5 functions downstream of the prolactin
receptor signaling pathway but upstream of STAT5 [48], both of which are required for differentiation
of the mammary alveolar epithelium [49].
Elf5 also plays a role in determining cell fate and stem cell function in the mammary epithelium,
as mammary-specific Elf5 deletion leads to an accumulation of mammary stem cells and the proportion
of cells with dual luminal/basal properties [50]. Elf5 deletion also resulted in EMT in the mammary
epithelium at lactation day 1, indicating its requirement for maintenance of the epithelial state [51].
1.3.3. ELF5 in the Kidney
In the kidney, ELF5 is specifically expressed in the principal cell lineage of the collecting ducts
and is induced by Notch signaling, a key regulator of this lineage. However, conditional deletion of
Elf5 in the developing collecting ducts had a minimal effect on principal cell differentiation, which
may be due to compensatory activation of other transcription factors, including other ESE members
such as Ehf, which also regulates aspects of principal cell differentiation [52].
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1.3.4. ELF5 in the Skin
Analysis of Elf5-LacZ mice in which the Elf5 coding region is replaced by the beta-galactosidase
(LacZ) reporter revealed that Elf5 is expressed in the differentiated cells of the inner root sheath of
the hair follicle [53]. Elf5 is also upregulated during keratinocyte differentiation in vitro [54], however
whether it is directly required for keratinocyte differentiation remains to be determined.
1.4. Role of ELF5 in Cancer
Examination of publicly accessible genomic data reveals mutations in ELF5 are relatively rare
in human cancers. Missense mutations occur in melanoma, mesothelioma, uterine, stomach and
colorectal cancers which are predominantly non-recurring missense of unknown function (Figure 5).
Figure 5. Genomic alterations in ELF5 in human cancers. Data from cancer bioportal. Only showing
cancers in which >50 cases were analysed.
Amplification of ELF5 occur in cancers of the upper GI tract (oesophageal and stomach), ovary,
head and neck, and breast in 2–6% of cases, while occasional deletions of ELF5 occur in prostate,
sarcoma, bladder, and lung cancers as well as acute myeloid leukemia (AML) and gliomas (Figure 5).
ELF5 is located within close proximity of the related ESE member EHF on chromosome 11p13
(Figure 6A), and analysis of a panel of various cancer cell lines indicates that EHF and ELF5 are
amplified or deleted in the same cases (Figure 6B), making identification of the driver gene in these
cases challenging.
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Figure 6. (A) Chromosomal location of ELF5 and EHF at location 11p13. (B) Amplification and deletion
pattern of ELF5 and EHF across a panel of cancer cell lines.
1.4.1. ELF5 in Breast Cancer
Both tumour promoting and suppressive roles for ELF5 have been reported in breast cancer, which
may be linked to the molecular subtype of the disease. In TNBCs, high ELF5 protein expression is
associated with worse outcome [55]. Comparatively, in the luminal A, luminal B, and HER2 subtypes,
ELF5 mRNA expression is reduced compared to the normal breast epithelium [51,56].
Direct evidence for a tumour suppressive role includes ELF5 silencing in epithelial-like T47D
breast cancer cells inducing EMT, and ELF5 re-expression in mesenchymal-like MDA-MB-231 cells
inducing epithelial features and reducing metastasis in vivo, at least in part by repressing expression
of SNAIL2 [51]. Similarly, deleting Elf5 in the MMTV-neu (HER2) background increased EMT markers
and the formation of lung metastases [51], while transgenic overexpression of Elf5 in the MMTV-PyMT
model of luminal breast cancer inhibited cell proliferation [57].
ELF5 has also been suggested to regulate oestrogen sensitivity of breast cancers, as ELF5 repressed
ER expression in MCF7 cells. Furthermore, ELF5 mRNA expression is increased in MCF7 cells made
resistant to tamoxifen by long term culture, and these cells were more dependent on ELF5 for their
proliferation [58].
1.4.2. ELF5 in Prostate, Urothelial, Ovarian and Renal Cancer
The majority of evidence generated to date indicates ELF5 plays a tumour suppressive role in
prostate [59,60], bladder [61], ovarian [62] and renal cancer [63]. In prostate cancer, loss of ELF5
protein expression correlates with loss of expression of the epithelial marker E-Cadherin and increased
expression of the mesenchymal marker N-Cadherin [59]. ELF5 knockdown in prostate cancer cell lines
induced EMT, particularly in the presence of TGFβ, and ELF5 was subsequently shown to block EMT
by inhibiting TGFβ signaling through binding and suppressing SMAD3 [59]. ELF5 was also found to
physically interact with AR in prostate cancer cells and repress its transcriptional activity. Furthermore,
ELF5 expression is induced upon AR activation in prostate cancer cells and is a transcriptional target
of AR, suggesting a role in negative feedback regulation of AR signaling [60].
Similarly, ELF5 mRNA and protein expression is decreased in urothelial (bladder) cancers
compared to the normal urothelium, and is inversely correlated with bladder cancer grade [61].
Downregulation of ELF5 in epithelial-like bladder cancer cell lines induced EMT, while its re-expression
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in mesenchymal-like T24 cells promoted MET [61]. The repression of ELF5 in urothelial cancers is
linked to promoter methylation, and can be reversed by treatment with the DNA methyltransferase
(DNMT) inhibitor 5-Azacytidine [61].
Finally, ELF5 mRNA expression in ovarian cancer [62] and ELF5 mRNA and protein in renal cell
carcinoma [63] is reduced compared to corresponding normal tissue, and re-expression of ELF5 in cell
line models of these cancers inhibits cell proliferation and survival [62,63].
1.5. Role of EHF in Normal Tissue Homeostasis
EHF is located on chromosome 11p13 within close proximity to ELF5 and encodes a 300 aa protein.
Analysis of the mRNA expression pattern of EHF across normal human tissues indicates highest
expression in the salivary gland, esophagus, vagina, prostate, colon, skin, bladder and breast (Figure 7).
In contrast to the other ESE factors, the impact of Ehf deletion in mice has not been reported.
Figure 7. Expression of EHF mRNA across normal human tissues. Data obtained from UCSC
genome browser.
1.5.1. EHF in the Airway Epithelium
EHF has been studied extensively as a potential modifier gene of the severity of the cystic fibrosis
phenotype. These studies stem from genome-wide association studies which identified a single
nucleotide polymorphism (SNP) associated with the severity of lung disease in cystic fibrosis patients
(rs12793173), which is located at chr11p13 within or close to potential EHF cis-regulatory elements [64].
Several subsequent studies sought to determine the role of EHF in bronchial epithelial cells where EHF
is basally expressed, and is induced in response to inflammatory mediators [65]. Direct EHF targets in
primary human bronchial epithelial cells are enriched for genes involved in lung pathology including
EMT and wound response, and knockdown of EHF reduced wound closure in bronchial epithelial
cells derived from both healthy and cystic fibrosis patients [66]. Most recently, a direct role for EHF
in repressing CFTR expression was demonstrated in bronchial epithelial cells, and EHF binding to a
regulatory region 35 kb upstream of the CFTR promoter was demonstrated by ChIP [67]. However,
a clear model of how this SNP may contribute to the cystic fibrosis phenotype is yet to emerge.
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1.5.2. EHF in the Skin
EHF plays an essential role in keratinocyte differentiation. Genome-wide profiling of enhancer
regions in keratinocytes identified the GGAA Ets motif as the most enriched transcription factor
binding site. As EHF was the ESE factor found to have the highest lineage-specific expression in
stratified epithelia, its role in keratinocyte differentiation was directly investigated by knockdown in
organotypic human epidermal tissue, revealing that EHF regulates ~400 genes in this tissue including
several associated with keratinocyte differentiation [68].
1.5.3. EHF in the Intestinal Epithelium
EHF mRNA and protein is highly expressed in the normal colon with maximal expression in the
proliferative stem-cell compartment of the crypt base [69], and is among the ~500 genes maximally
expressed in LGR5+ intestinal stem cells [70]. Ehf mRNA is also highly expressed in specialised M
(microfold cells) cells which are located in the follicle-associated epithelium (FAE) which overlies
Payer’s patches in the intestine. Here, M cells contribute to immune surveillance by mediating
transcytosis of potential antigens from the intestinal lumen into the underlying immune cells [71].
EHF promoter activity was induced in the Caco-2 cell line model of FAE, and ectopic expression
of EHF in this model induced expression of transcytosis associated genes. Notably however, EHF
overexpression was not sufficient to induce M cell differentiation in this model, suggesting EHF may
promote functional maturation of the FAE rather than M cell differentiation [72].
1.5.4. EHF in Non-Epithelial Cells
While EHF mRNA and protein expression is highest in epithelial cells, there is also evidence that
EHF is expressed in different components of the innate immune system, particularly dendritic cells
(DCs) [73,74], where EHF is upregulated during cytokine-induced maturation of DCs, and knockdown
of EHF impairs the maturation process [73].
EHF also plays a role in suppressing activation of mast cells, the major effector of IgE-driven
hypersensitivity. TGFβ suppresses mast cell activation, inducing EHF mRNA and protein
expression during this process. Overexpression of EHF in mast cells mimicked several of the
TGFβ-induced transcriptional changes and inhibited mast cell degranulation, suggesting a direct
role in TGFβ-mediated suppression of mast cell activity [75], although knockdown or knockout studies
are still needed to confirm these findings.
1.6. Role of EHF in Cancer
Mutations in EHF are relatively rare in human cancers and those which do arise are predominantly
non-recurring missense mutations (Figure 8). However, occasional truncating mutations occur in
gastric, uterine and cervical cancers, suggestive of a potential tumour suppressive role (Figure 8).
Conversely, EHF amplifications occur in a subset of oesophageal, ovarian, stomach, bladder, and head
and neck cancers, however, as discussed above, EHF is located within close proximity to ELF5 and
has an amplification and deletion profile which is very similar to ELF5 (Figure 6), making it difficult
to determine whether one, or perhaps both, transcription factors provides a selective advantage for
these tumours.
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Figure 8. Genomic alterations in EHF in human cancers. Data from cancer bioportal. Only showing
cancers in which >50 cases were analysed.
1.6.1. EHF in Gastric and Colorectal Cancer.
The rate of EHF amplification in GC identified in large genomic studies is ~4%, however,
Shi et al. reported EHF amplification in ~40% of cases, which was associated with worse outcome [76].
Nevertheless, consistent with an oncogenic role in this disease, EHF knockdown inhibited proliferation,
survival, migration and invasion of GC cell lines in vitro and in vivo. In terms of mechanism, EHF was
shown to drive GC progression through direct transactivation of the HER2 promoter, and activation of
downstream MAPK and PI3K/AKT signaling [76].
In CRCs, a study by Taniue et al. suggested that EHF is required for the survival of TP53 wild-type
CRC cell lines. Knockdown of EHF in the TP53 wild-type HCT116 CRC cell line reduced expression of
RUVBL1, an ATPase associated with chromatin remodeling and a repressor of TP53 expression [77].
However direct induction of TP53 following EHF knockdown was not demonstrated.
1.6.2. EHF in Thyroid Cancer
EHF mRNA and protein is expressed in papillary thyroid cancers (PTCs) and EHF knockdown in
PTC cell lines inhibits cell proliferation, invasion and migration in vitro and in vivo. As observed in gastric
cancers, EHF mRNA expression correlated with HER2 and HER3 expression in primary PTCs, and EHF
was shown to directly bind and transactivate the HER2 and HER3 promoters in PTC cell lines [78].
1.6.3. EHF in Ovarian Cancer
A tumour promoting role for EHF has also been suggested in ovarian cancer (OC), where EHF
mRNA is overexpressed and correlates with poor overall survival [79]. Knockdown of EHF in OC
cell lines inhibited cell proliferation, which was associated with reduced expression of Cyclin B1 and
Cyclin D1, and upregulation of the cyclin-dependent kinase inhibitor, p21. EHF knockdown also
inhibited migration and invasion of OC cell lines, and reduced expression of MMP9 [79].
1.6.4. EHF in Prostate Cancer
In contrast to the tumour promoting roles described above, a tumour suppressive role for EHF
is described in prostate, pancreatic and oesophageal cancers. In prostate cancer, EHF mRNA and
protein expression is decreased, which is linked to methylation of a conserved CpG residue within the
EHF promoter [80]. Loss of EHF expression is more pronounced in tumours with higher expression
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of cancer stem cell markers, and is associated with poorer patient outcome. Re-expression of EHF
in prostate cancer cells inhibited clonogenic survival and induced apoptosis by directly driving
caspase-3 expression [80]. Subsequent studies demonstrated that EHF re-expression in prostate
cancer cells inhibited stem like properties and promoted epithelial differentiation by repressing EMT
drivers, such as TWIST1, ZEB2, NANOG and POU5F1 [81]. This effect was mechanistically linked
to EHF-mediated repression of the Lin28a and Lin28b RNA binding proteins, and re-expression of
members of the let-7 family of miRNAs [82]. EHF also represses IL-6 in prostate epithelial cells by
directly binding the IL-6 promoter, and EHF loss drives tumour progression by de-repression of IL-6,
and subsequent stimulation of STAT3 signaling [82]. Finally, Kunderfranco et al. demonstrated that
EHF contributes to tumour suppression of prostate cancer cells by repressing expression of EZH2 and
promoting expression of the tumour suppressor Nkx3.1 [83].
1.6.5. EHF in Pancreatic and Oesophageal Cancer
EHF protein expression is downregulated in pancreatic ductal adenocarcinomas (PDAC), which
is associated with poorer differentiation grade and worse patient outcome. EHF knockdown in PDAC
cell lines promoted cell motility and invasiveness, and increased metastasis in an orthotopic model,
which was linked to repression of its direct transcriptional target, E-Cadherin [84].
In oesophageal squamous cell carcinoma (ESCC), the primary mechanism of EHF protein
dysregulation is altered subcellular localization, where in contrast to its predominantly nuclear
expression in the normal oesophageal epithelium, EHF is localized to the cytoplasm. While the
mechanisms driving the cytoplasmic localization of EHF are yet to be defined, re-expression of EHF in
ESCC cell lines which restored its nuclear expression, inhibited cell proliferation, colony formation,
migration, and invasion [85].
1.7. Role of SPDEF in Normal Tissue Homeostasis
Finally, SPDEF is localized to chromosome 6p21.31 and encodes a 335 aa protein. In contrast
to ELF3, ELF5 and EHF, which preferentially bind to the GGAA motif, SPDEF preferentially binds
to GGAT [86]. Analysis of SPDEF mRNA expression across normal human tissues indicates high
expression in the prostate, salivary gland, stomach, colon and breast (Figure 9).
Figure 9. Expression of SPDEF mRNA across normal human tissues. Data obtained from UCSC
genome browser.
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1.7.1. Spdef Knockout Mice
Two mouse models of Spdef deletion have been generated [87,88]. The Clevers lab generated a
Spdef knockout strain in which Exon 6 encoding the DNA binding domain was deleted. These mice
were born at the expected Mendelian ratios and were fertile, however displayed reduced numbers
and impaired terminal differentiation of goblet cells in the intestinal [87], conjunctival [89,90] and
tracheobronchial mucosa [91]. Transgenic overexpression of SPDEF in nonciliated respiratory epithelial
cells [92], or intestinal epithelial cells, induced expansion of goblet cells in these tissues supporting a
role for SPDEF as a goblet cell lineage determinant [93].
Horst et al. developed an independent Spdef−/− strain in which exons 2-5 encoding the transactivation
domain, the PNT domain, and most of the ETS DNA-binding domain were deleted [88]. These mice were
also viable and fertile, although a modest decrease in the percentage of Spdef−/− mice was noted from
heterozygote matings (18% vs. 25%). Notably, 40% of Spdef−/− mice developed thickening of the antral
stomach by 4 months, and half of the Spdef−/− mice developed mucosal hyperplasia of the gastric antrum
during the course of their lifetime, which was preceded by submucosal infiltration of inflammatory cells.
Deletion of Spdef impaired differentiation of antral mucous gland cells, consistent with its common role in
regulating differentiation of the goblet cell lineage in multiple tissues [88].
1.7.2. SPDEF in the Prostate Epithelium
While no phenotype in the normal prostate of Spdef−/− mice has been described, SPDEF mRNA is
highly expressed in the terminally differentiated secretory luminal cells of the prostate epithelium [94].
SPDEF also interacts with the DNA binding domain of AR, and synergistically activates the PSA gene
promoter [94].
1.7.3. Role of SPDEF in Cancer
Mutations in SPDEF are rare in human cancers, with the majority of mutations being non-recurring
missense mutations (Figure 10). One exception is gastric cancer, where truncating mutations in SPDEF
are observed in a small subset of cases. The phenotype of Spdef−/− mice, which develop gastric mucosal
hyperplasia [88], suggests these truncating mutations may be pathogenic. In addition, amplifications
of SPDEF are found in a small subset of melanomas, esophageal, ovarian, uterine, lung and liver
cancers (Figure 10), however the significance of these events in disease initiation or progression has
yet to be directly tested.
Figure 10. Genomic alterations in SPDEF in human cancers. Data from cancer bioportal. Only showing
cancers in which >50 cases were analysed.
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The functional role of SPDEF in progression of several cancers has been investigated, including
CRC, HCC, bladder, prostate and ovarian cancer. In each of these cases, the majority of evidence
suggests a tumour suppressive role, which are described below.
1.7.4. SPDEF in Colorectal Cancer
SPDEF mRNA and protein expression is decreased in primary CRCs and CRC cell lines compared
to the normal colonic epithelium [95,96], and SPDEF re-expression in CRC cell lines induces cell
cycle arrest, apoptosis and inhibits cell migration. Conversely, SPDEF knockdown in HT29 CRC cells
increased cell proliferation [96]. These findings were validated in animal models, where adenoma
formation was significantly increased when Spdef−/− mice were crossed to ApcMin/+ mice or challenged
with DSS/AOM [95]. Conversely, transgenic expression of Spdef in ApcMin/+ mice reduced the mitotic
rate of these adenomas [95].
Mechanistically, overexpression of SPDEF in mouse intestinal adenomas or CRC cell lines
decreased WNT signaling [95]. A physical interaction between the PNT domain of SPDEF and the
Armadillo repeats on β-catenin was subsequently demonstrated, which disrupted β-catenin binding
to TCF/LEF proteins and displaced β-catenin from promoter/enhancer regions of cell cycle genes,
inducing cellular quiescence [97].
1.7.5. SPDEF in Hepatocellular Cancer
SPDEF mRNA and protein expression is reduced in HCC, particularly in poorly differentiated
tumours, and is associated with worse patient outcome [98]. Knockdown of SPDEF in HCC cell lines
increased cell proliferation, survival and invasion in vitro and tumour growth and metastasis in vivo.
The increased invasion and metastasis are likely due to increased expression of the EMT driver, SLUG.
Comparatively, overexpression of SPDEF in HCC cell lines decreased proliferation and increased
apoptosis [98].
1.7.6. SPDEF in Bladder Cancer
SPDEF mRNA and protein expression is decreased in bladder cancer, particularly in high grade
tumours, and re-expression of SPDEF in bladder cancer cell lines inhibited proliferation and invasion
in vitro, and reduced xenograft growth in vivo. SPDEF re-expression also reduced EMT markers,
while SPDEF knockdown induced the opposite effect [99].
1.7.7. SPDEF in Prostate Cancer
In prostate cancer, loss of SPDEF protein correlates with poor differentiation and worse
patient outcome, which is also reflected in prostate cancer cell lines where more aggressive lines
express lower SPDEF [100,101]. Re-expression of SPDEF in SPDEF-negative PC3 cells inhibited cell
migration, invasion and metastasis [100,102], while SPDEF knockdown in LNCaP cells promoted
these processes [100,102]. Finally, deletion of Spdef in mice increased prostate tumour formation in the
TRAMP model, while transgenic overexpression of Spdef reduced tumorigenesis [103]. Mechanistically,
Spdef directly repressed expression of Foxm1, a key transcription factor required for tumour cell
proliferation, and reduced expression of multiple Foxm1 target genes involved in cell cycle progression
including Cdc25b, Cyclin B1, Cyclin A2 [103].
SPDEF is also regulated by AR signalling in prostate cancer, which has both beneficial and
potentially detrimental effects when AR signaling is inhibited by androgen deprivation therapy (ADT).
Specifically, AR-mediated activation of SPDEF repressed expression of TGFBI and CCL2, key drivers
of prostate cancer metastasis [104,105]. ADT relieves this repression and inadvertently promotes
metastasis by increasing TGFBI and CCL2 expression, providing an example of how a therapy which
blocks growth of the primary tumour may paradoxically promote metastasis.
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1.7.8. SPDEF in Ovarian Cancer
Initially, SPDEF mRNA and protein was reported to be overexpressed in ovarian cancer (OC),
particularly serous epithelial ovarian tumours [106,107]. However, SPDEF mRNA and protein
expression was later found to be lower in OC compared to non-neoplastic tissue, and retention
of SPDEF found to be a favourable prognostic marker [108]. Supporting a tumour suppressive role,
SPDEF re-expression in SPDEF-negative OC cells inhibited cell proliferation and induced apoptosis,
which was associated with reduced expression and promoter activity of the pro-survival gene, survivin
(BIRC5) [108].
1.7.9. SPDEF in Breast Cancer
Similar to other ESE members, the role of SPDEF in breast cancer also varies according to the
molecular subtype of the disease. In TNBC, a tumour suppressive role is suggested by the loss of
SPDEF protein in TNBC cell lines [109,110], which has been linked to inhibition of translation of SPDEF
mRNA by miR-204 and miR-510 [111]. Furthermore, SPDEF re-expression inhibits the growth and
migration of the TNBC cell line, MDA-MB-231 [109,110].
Conversely, in ER+ breast cancers, SPDEF mRNA is overexpressed and correlates with poor
overall survival [112,113]. Similarly, knockdown of SPDEF in multiple luminal cell lines inhibited
proliferation, increased basal apoptosis, and increased sensitivity to the ER antagonists, tamoxifen
and fulvestrant [114]. This finding was subsequently validated in a genome-wide shRNA screen of
multiple breast cancer cell lines which identified SPDEF and FOXA1 as the two most essential genes
required for the growth and survival of luminal/HER2 cell lines [115]. Similar to the findings reported
for ELF5, SPDEF expression was also elevated in MCF7 cells made resistant to tamoxifen, and SPDEF
knockdown in these lines resulted in extensive apoptosis, suggesting SPDEF may also play a role in
resistance to endocrine therapy [114].
1.8. ESE Transcription Factors as Therapeutic Targets in Cancer
As outlined in this review, there is now strong evidence that the ESE transcription factors
contribute to the progression of several cancers, functioning as either tumour promoters or inhibitors,
depending on the tumour type, and in some cases tumour subtype. While inactivating mutations
in these factors occurs occasionally in cancers, in the majority of cases ESE factors impact tumour
progression as a consequence of their altered expression. In cases where tumour progression is driven
by their overexpression, developing treatments to inhibit ESE function represents a logical approach.
In this context, a potential advantage of targeting ESE transcription factors for cancer treatment is
their relatively restricted expression across tissues, which may limit toxicities. Proof of concept for
this approach lies in the effective therapeutic targeting of ER and AR in breast and prostate cancer,
which exploits the lineage-specific functionality of these transcription factors rather than their genetic
alteration, to create a therapeutic window. The potential for targeting specific ESE factors is also
supported by the survival of Elf3−/− and Spdef−/− mice.
Comparatively, where loss of expression of ESE transcription factors drives tumorigenesis,
therapeutic opportunities may be limited to re-inducing their expression or targeting the pathways
or cellular processes which are activated as a consequence. In this context, a recurring theme is the
requirement of several ESE factors for maintenance of the epithelial state of many cancers. Therapies
which re-induce ESE factors may therefore have specific use in metastasis prevention, or may provide
secondary benefit subsequent to re-epithelialization of cancers, such as improving drug response.
Potential strategies by which ESE factors may be inhibited or activated are discussed below.
1.8.1. Direct Targeting
While the direct targeting of transcription factors has traditionally been considered challenging
due to the difficulty in directly modulating protein/DNA binding, a number of clinical successes have
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highlighted the therapeutic value of transcription factor targeting for cancer treatment. This includes
the use of inhibitors of the nuclear receptors ER, AR and GR (Glucocorticoid receptor) for the treatment
of breast, prostate and lymphoid cancers, respectively, and the use of all trans retinoic acid for treating
acute promyelocytic leukemia patients harboring PML-RARα gene fusions [116].
Although there are currently no small molecules that can directly target ESE transcription factors,
several approaches can be envisioned. These include the use of decoy oligonucleotides which mimic
ETS binding sites to saturate ESE factors as previously tested for Ets1 in a model of gastric cancer [117],
or specific DNA-binding compounds which block transcription factor-DNA interactions as described
for Sp1 [118], NF-κB [119], EVI1 [120] and the ETS factor, ERG1 [121]. However, a likely limitation
of this approach is non-specific DNA targeting which may particularly impact the targeting of ESE
factors where multiple ETS family members bind the same DNA motif.
Several ESE factors co-operate with other transcription factors or co-factors to modulate gene
expression which also creates therapeutic opportunities. For example, ELF3 interacts with AR and ER
and inhibits their transcriptional activity [35,42]. Similarly, SPDEF and ELF3 bind to and inhibit the
transcriptional activity of β-catenin in CRC cells [33,97]. Compounds that promote or mimic these
interactions may therefore have therapeutic potential. Notably, Gajulapalli et al. performed molecular
docking studies to map the minimal region of ELF3 which interacts with the DNA binding domain
of ERα. Based on these findings, they developed a synthetic 17 aa ELF3 peptide of this region which
inhibited the DNA binding activity of ERα and proliferation of ERα positive but not ERα negative
breast cancer cell lines [35].
1.8.2. Indirect Targeting
An alternative strategy for targeting transcription factors is to disrupt their interaction with
key transcriptional co-factors. These include epigenetic regulators such as histone aceyltransferases,
deacetylases, methylases and demethylases. These regulators are recruited by transcription factors
to modify surrounding chromatin, or to induce post-translational modification of the transcription
factors themselves. For example, ELF3 interacts with the histone acetyltransferases p300 and CBP,
which increases its transcriptional activity [122,123]. Further studies to identify the transcriptional
activators and repressors which interact with ESE factors represents a promising field of investigation,
as a number of small molecule inhibitors of transcriptional co-repressors and co-activators have now
been generated, with several in clinical use [124].
1.8.3. Targeting Pathways Altered by ESE Factors in Cancer
In cases where ESE factors are genetically inactivated, targeting the pathways and processes
which are consequently activated may represent a viable strategy. For example, loss of EHF in prostate
cancer activates JAK/STAT signaling and sensitizes cells to treatment with a JAK2 inhibitor [82].
Conversely, overexpression of EHF drives HER2 expression in gastric and thyroid cancers, sensitizing
these tumours to HER2 inhibition, while in lung cancer cell lines, ELF3 overexpression activates the
PI3K/AKT and MAPK pathways and sensitized lung cancer cells to inhibitors of these pathways [43].
1.8.4. Re-inducing Expression of ESE Factors
A further mechanism of ESE transcription factor suppression in cancer is via promoter
methylation, which has been reported for EHF in prostate [80] and pancreatic cancer [84], and for
ELF5 in bladder cancer [61]. In these cases, treatment with a demethylating agent re-induced their
expression [61,84]. A limitation of this approach, however, is the broad ranging transcriptional
effects of demethylating agents. Importantly, promoter methylation can be a reflection of altered
transcription [125], therefore detailed study of the specific mechanisms which predispose these
promoters to transcriptional downregulation and methylation may identify more specific strategies for
re-inducing their expression.
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2. Conclusions
As outlined in this review, the ESE transcription factors play a critical role in the development and
differentiation of a number of epithelial tissues. There is also now strong evidence directly implicating
either the gain of loss or these transcription factors in cancer progression, which is dependent on
tumour type and in some cases, tumour subtype. While additional studies, particularly confirmation
of findings in mouse models of cancer, are still required in some cases, the challenge now is to develop
novel cancer treatments focused on either direct targeting of these factors, re-inducing their expression,
or targeting the pathways disrupted as a consequence of ESE factor deregulation.
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